Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer?

Jessica T. Lee, John F P Bridges, Lillie Shockney

Research output: Contribution to journalArticle

Abstract

Breakthroughs in genetic testing have informed patients and physicians in the treatment of breast cancer; however, they have also added to the complexity of decision-making. Genetic testing for breast cancer susceptibility not only changes treatment and screening options, but also challenges the way in which interventions are evaluated. While comparative effectiveness and cost-effective analysis methods are now standard for evaluation at the societal level. technologies such as genetic testing require us to consider the role of patient preference, especially as we move towards more personalized approaches to medicine. In this review, we discuss the changing role of pharmacoeconomic and outcomes research by highlighting how the discipline could use patient preference methods, such as conjoint analysis, to promote shared decision-making and to empower breast cancer patients. By adopting these methods we could move our focus from what is best for payers or society to one that applies scientific methods to identify what is best for patients.

Original languageEnglish (US)
Pages (from-to)73-79
Number of pages7
JournalExpert Review of Pharmacoeconomics and Outcomes Research
Volume8
Issue number1
DOIs
StatePublished - Feb 2008

Fingerprint

Pharmaceutical Economics
Genetic Testing
Outcome Assessment (Health Care)
Breast Neoplasms
Patient Preference
Decision Making
Cost-Benefit Analysis
Medicine
Technology
Physicians
Power (Psychology)
Therapeutics

Keywords

  • Breast cancer
  • Conjoint analysis
  • Genetic testing
  • Health economics
  • Patient preferences
  • Personalized medicine
  • Shared decision-making

ASJC Scopus subject areas

  • Pharmacology
  • Medicine (miscellaneous)

Cite this

Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer? / Lee, Jessica T.; Bridges, John F P; Shockney, Lillie.

In: Expert Review of Pharmacoeconomics and Outcomes Research, Vol. 8, No. 1, 02.2008, p. 73-79.

Research output: Contribution to journalArticle

@article{1e5d083cc2934a0996046e401ef13b40,
title = "Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer?",
abstract = "Breakthroughs in genetic testing have informed patients and physicians in the treatment of breast cancer; however, they have also added to the complexity of decision-making. Genetic testing for breast cancer susceptibility not only changes treatment and screening options, but also challenges the way in which interventions are evaluated. While comparative effectiveness and cost-effective analysis methods are now standard for evaluation at the societal level. technologies such as genetic testing require us to consider the role of patient preference, especially as we move towards more personalized approaches to medicine. In this review, we discuss the changing role of pharmacoeconomic and outcomes research by highlighting how the discipline could use patient preference methods, such as conjoint analysis, to promote shared decision-making and to empower breast cancer patients. By adopting these methods we could move our focus from what is best for payers or society to one that applies scientific methods to identify what is best for patients.",
keywords = "Breast cancer, Conjoint analysis, Genetic testing, Health economics, Patient preferences, Personalized medicine, Shared decision-making",
author = "Lee, {Jessica T.} and Bridges, {John F P} and Lillie Shockney",
year = "2008",
month = "2",
doi = "10.1586/14737167.8.1.73",
language = "English (US)",
volume = "8",
pages = "73--79",
journal = "Expert Review of Pharmacoeconomics and Outcomes Research",
issn = "1473-7167",
publisher = "Expert Reviews Ltd.",
number = "1",

}

TY - JOUR

T1 - Can pharmacoeconomics and outcomes research contribute to the empowerment of women affected by breast cancer?

AU - Lee, Jessica T.

AU - Bridges, John F P

AU - Shockney, Lillie

PY - 2008/2

Y1 - 2008/2

N2 - Breakthroughs in genetic testing have informed patients and physicians in the treatment of breast cancer; however, they have also added to the complexity of decision-making. Genetic testing for breast cancer susceptibility not only changes treatment and screening options, but also challenges the way in which interventions are evaluated. While comparative effectiveness and cost-effective analysis methods are now standard for evaluation at the societal level. technologies such as genetic testing require us to consider the role of patient preference, especially as we move towards more personalized approaches to medicine. In this review, we discuss the changing role of pharmacoeconomic and outcomes research by highlighting how the discipline could use patient preference methods, such as conjoint analysis, to promote shared decision-making and to empower breast cancer patients. By adopting these methods we could move our focus from what is best for payers or society to one that applies scientific methods to identify what is best for patients.

AB - Breakthroughs in genetic testing have informed patients and physicians in the treatment of breast cancer; however, they have also added to the complexity of decision-making. Genetic testing for breast cancer susceptibility not only changes treatment and screening options, but also challenges the way in which interventions are evaluated. While comparative effectiveness and cost-effective analysis methods are now standard for evaluation at the societal level. technologies such as genetic testing require us to consider the role of patient preference, especially as we move towards more personalized approaches to medicine. In this review, we discuss the changing role of pharmacoeconomic and outcomes research by highlighting how the discipline could use patient preference methods, such as conjoint analysis, to promote shared decision-making and to empower breast cancer patients. By adopting these methods we could move our focus from what is best for payers or society to one that applies scientific methods to identify what is best for patients.

KW - Breast cancer

KW - Conjoint analysis

KW - Genetic testing

KW - Health economics

KW - Patient preferences

KW - Personalized medicine

KW - Shared decision-making

UR - http://www.scopus.com/inward/record.url?scp=40849120194&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=40849120194&partnerID=8YFLogxK

U2 - 10.1586/14737167.8.1.73

DO - 10.1586/14737167.8.1.73

M3 - Article

C2 - 20528358

AN - SCOPUS:40849120194

VL - 8

SP - 73

EP - 79

JO - Expert Review of Pharmacoeconomics and Outcomes Research

JF - Expert Review of Pharmacoeconomics and Outcomes Research

SN - 1473-7167

IS - 1

ER -